Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Platinum-based chemotherapy remains the standard-of-care for most patients affected by advanced non-small cell lung cancer (NSCLC). The platinum compounds currently used in NSCLC are cisplatin and carboplatin. The availability of new generation drugs has led to the adoption of schedules with lower doses of platinum compounds leading to increased tolerability. Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. Recent evidence emphasized that the optimal number of first-line platinum cycles should be four for any NSCLC histology. New platinum compounds and the use of functional genomics to deliver platinum drugs as personalised medicine, are being investigated. Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537 · cited 2×
“4 CONCERNS IN THE USE OF CISPLATIN AND CARBOPLATIN Platinum compounds attack, indiscriminately, all rapidly dividing cells leading to severe side effects and inducing the ability of cancers to develop drug resistance [1].”
BackgroundComparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955 · cited 1×
“Nine trials addressed this relevant issue in patients affected by advanced NSCLC [31-39] (Table 1).”
BackgroundCOMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“To date, four main mechanisms able to induce platinum resistance have been identified, including: (i) reduced cellular uptake of the platinum salt; (ii) increased repair of platinuminduced DNA damage; (iii) degradation and detoxification of the drugs inside the cells by glutathione; and (iv) altered apoptosis [17, 18].”
BackgroundOzols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866 · cited 1×
“The dose of carboplatin is usually tailored for each patient using the area under the concentration-time curve (AUC) and renal function of the patient, because this drug is characterized by an extensive renal excretion [23, 24].”
MethodPfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413 · cited 1×
“In 2003, ASCO guidelines recommended that chemotherapy should be stopped at four cycles in patients who are not responding to treatment and that no more than six cycles should be administered [43].”
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“For example, randomized studies on ovarian cancer supported the use of carboplatin instead of cisplatin [28, 29], while cisplatin is considered superior to carboplatin for germ cell and head-neck tumors [30].”
BackgroundFossella, F., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.046 · Cited by 939 · cited 1×
“Nine trials addressed this relevant issue in patients affected by advanced NSCLC [31-39] (Table 1).”
BackgroundPeters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K., & Felip, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds226 · Cited by 930
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915 · cited 1×
“These last recommendations were confirmed in 2009, 2011 and 2015 ASCO guideline updates [26, 44, 45].”
BackgroundMasters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K. M., & Peters, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu199 · Cited by 679 · cited 2×
“In 2014, European Society of Medical Oncology (ESMO) metastatic NSCLC guidelines recommend, for most patients, four cycles of chemotherapy, with a maximum of six cycles [27].”
BackgroundArdizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk196 · Cited by 612
NSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604
Owonikoko, T. K., Ragin, C. C., Belani, C. P., Oton, A. B., Gooding, W. E., Taioli, E., & Ramalingam, S. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5435 · Cited by 566 · cited 1×
“Approximately 50% of new lung cancer cases are diagnosed in patients aged more than 70 years, and about 15% in patients aged more than 80 years [19].”
BackgroundHotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.109 · Cited by 364
D'Addario, G., Pintilie, M., Leighl, N. B., Feld, R., Cerny, T., & Shepherd, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.045 · Cited by 363
(1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2996 · Cited by 355
Delbaldo, C., Michiels, S., Syz, N., Soria, J.-C., Le Chevalier, T., & Pignon, J.-P. (2004) · JAMA · doi:10.1001/jama.292.4.470 · Cited by 337 · cited 1×
“Another meta-analysis investigated the role of adding a third agent to platinum-based doublets and showed that triplets are associated with an increase in objective response rate (ORR) which does not translate in a better progression-free survival (PFS) or OS rate but with an increased toxicity [6].”
BackgroundSmith, I. E., O’Brien, M. E. R., Talbot, D. C., Nicolson, M. C., Mansi, J. L., Hickish, T. F., Norton, A., & Ashley, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1336 · Cited by 308 · cited 2×
“Five trials addressed this question [49-53] (Table 3), but only four studies were included in”
Carboplatin versus cisplatin in solid tumors: An analysis of the literature
Lokich, J., & Anderson, N. (1998) · Annals of Oncology · doi:10.1023/a:1008215213739 · Cited by 304 · cited 1×
“For example, randomized studies on ovarian cancer supported the use of carboplatin instead of cisplatin [28, 29], while cisplatin is considered superior to carboplatin for germ cell and head-neck tumors [30].”
BackgroundRizzo, J. D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M. O., Spivak, J. L., Bennett, C. L., Bohlius, J., Evanchuk, D., Goode, M. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2201 · Cited by 303
Rosell, R., Gatzemeier, U., Betticher, D. C., Keppler, U., Macha, H. N., Pirker, R., Berthet, P., Breau, J. L., Lianes, P., Nicholson, M., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf332 · Cited by 299 · cited 1×
“Nine trials addressed this relevant issue in patients affected by advanced NSCLC [31-39] (Table 1).”
BackgroundAzzoli, C. G., Temin, S., Aliff, T., Baker, S., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2774 · Cited by 285 · cited 1×
“These last recommendations were confirmed in 2009, 2011 and 2015 ASCO guideline updates [26, 44, 45].”
Preclinical Perspectives on Platinum Resistance
Kelland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00001 · Cited by 280 · cited 1×
“To date, four main mechanisms able to induce platinum resistance have been identified, including: (i) reduced cellular uptake of the platinum salt; (ii) increased repair of platinuminduced DNA damage; (iii) degradation and detoxification of the drugs inside the cells by glutathione; and (iv) altered apoptosis [17, 18].”
BackgroundThe state-of-play and future of platinum drugs
Apps, M. G., Choi, E. H. Y., & Wheate, N. J. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0237 · Cited by 256 · cited 1×
“In the last years, the research to discover new platinum compounds is also being focused in either prevent drug degradation or better target tumours via passive or active mechanisms [54].”
BackgroundKlastersky, J., Sculier, J. P., Lacroix, H., Dabouis, G., Bureau, G., Libert, P., Richez, M., Ravez, P., Vandermoten, G., & Thiriaux, J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1556 · Cited by 246 · cited 1×
“Nine trials addressed this relevant issue in patients affected by advanced NSCLC [31-39] (Table 1).”
BackgroundSoon, Y. Y., Stockler, M. R., Askie, L. M., & Boyer, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4522 · Cited by 198
Antiemetics: American Society of Clinical Oncology Focused Guideline Update
Hesketh, P. J., Bohlke, K., Lyman, G. H., Basch, E., Chesney, M., Clark-Snow, R. A., Danso, M. A., Jordan, K., Somerfield, M. R., & Kris, M. G. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3635 · Cited by 191
Park, J. O., Kim, S.-W., Ahn, J. S., Suh, C., Lee, J. S., Jang, J. S., Cho, E. K., Yang, S. H., Choi, J.-H., Heo, D. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8134 · Cited by 180 · cited 2×
“Five trials addressed this question [49-53] (Table 3), but only four studies were included in”
Cisplatin-associated anemia: an erythropoietin deficiency syndrome.
Wood, P. A., & Hrushesky, W. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117840 · Cited by 164 · cited 1×
“Several mechanisms can led to anemia, including depletion of intrinsic erythropoietin production (caused by peritubular renal cell depletion), reduced bone marrow stem cell activity and the absence of the stem cell reaction to administered erythropoietin [8-10].”
BackgroundPlatinum compounds in children with cancer: toxicity and clinical management
Ruggiero, A., Trombatore, G., Triarico, S., Arena, R., Ferrara, P., Scalzone, M., Pierri, F., & Riccardi, R. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283650bda · Cited by 160 · cited 1×
“These dose reductions, could increase the chance to develop resistance by cancer cells [16].”
BackgroundZatloukal, P., Petruželka, L., Zemanová, M., Kolek, V., Skřičková, J., Pešek, M., Fojtů, H., Grygárková, I., Sixtová, D., Roubec, J., et al. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00233-2 · Cited by 160
for the Norwegian Lung Cancer Study Group, von Plessen, C., Bergman, B., Andresen, O., Bremnes, R. M., Sundstrøm, S., Gilleryd, M., Stephens, R., Vilsvik, J., Aasebø, U., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603383 · Cited by 158
Rossi, A., Chiodini, P., Sun, J., O'Brien, M. E. R., von Plessen, C., Barata, F. J., Park, K., Popat, S., Bergman, B., Parente, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70402-4 · Cited by 119 · cited 3×
“The curves shown in this figure are obtained from the database used for the individual patient data meta-analysis [48] and have not been published before.”
BackgroundMethodInfluentialSelf-citationDeben, C., Deschoolmeester, V., Lardon, F., Rolfo, C. D., & Pauwels, P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.019 · Cited by 91
Hubner, R. A., Riley, R. D., Billingham, L. J., & Popat, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025164 · Cited by 88
Cancer and Age: General Considerations
Hoffe, S. E., & Balducci, L. (2012) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.09.001 · Cited by 87 · cited 1×
“Aging may be associated with decreased physiologic reserve, comorbidity and polypharmacy, functional dependence, and inadequate social support, which lead to limited life expectancy with a potential reduced tolerance to cancer chemotherapy [20].”
BackgroundMazzanti, P., Massacesi, C., Rocchi, M., Mattioli, R., Lippe, P., Trivisonne, R., Buzzi, F., Signoribus, G. D., Tuveri, G., Rossi, G. E., et al. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00140-5 · Cited by 78 · cited 1×
“Nine trials addressed this relevant issue in patients affected by advanced NSCLC [31-39] (Table 1).”
BackgroundRoth, J. A., & Carlson, J. J. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.04.005 · Cited by 68 · cited 1×
“Three meta-analyses [55-57], supported this hypothesis.”
Paccagnella, A., Favaretto, A. G., Oniga, F., Barbieri, F., Ceresoli, G. L., Torri, V., Villa, E., Verusio, C., Cetto, G., Santo, A., et al. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00280-0 · Cited by 66 · cited 1×
“Nine trials addressed this relevant issue in patients affected by advanced NSCLC [31-39] (Table 1).”
BackgroundPharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy
Santabarbara, G., Maione, P., Rossi, A., & Gridelli, C. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1122757 · Cited by 62 · cited 1×
“Several therapeutic approaches have been developed and are under investigation to reduce or prevent these effects with very contrasting results [14].”
Self-citationCisplatin-Associated hemolytic uremic syndrome
Canpolat, C., Pearson, P., & Jaffe, N. (1994) · Cancer · doi:10.1002/1097-0142(19941201)74:11<3059::aid-cncr2820741125>3.0.co;2-z · Cited by 60 · cited 1×
“Several mechanisms can led to anemia, including depletion of intrinsic erythropoietin production (caused by peritubular renal cell depletion), reduced bone marrow stem cell activity and the absence of the stem cell reaction to administered erythropoietin [8-10].”
Studying Cancer Treatment in the Elderly Patient Population
Balducci, L. (2014) · Cancer Control · doi:10.1177/107327481402100306 · Cited by 58 · cited 1×
“treatment decisions are based on results of trials conducted in substantially younger individuals [21].”
Lima, J. P. D. S. N., dos Santos, L. V., Sasse, E. C., & Sasse, A. D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.006 · Cited by 52 · cited 1×
“To answer to the question concerning the optimal number of treatment cycles to administer in the first-line treatment of advanced NSCLC, several meta-analyses based on abstracted data showed that more than four cycles was associated with a longer PFS, without statistically significant differences in OS but with increa…”
BackgroundZatloukal, P., Petruzelka, L. B., Zemanová, M., Kolek, V., Skřičková, J., Pešek, M., Sixtová, D., Roubec, M., Havel, L., & Průša, P. (2003) · Lung Cancer · Cited by 46
Jelić, S., Mitrović, L., Radosavljevic, D. Z., Elezar, E., Babović, N. L., Kovčin, V., Tomašević, Z., Kovačević, S., Gavrilović, D., & Radulovic, S. S. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00239-2 · Cited by 44 · cited 1×
“Nine trials addressed this relevant issue in patients affected by advanced NSCLC [31-39] (Table 1).”
BackgroundBronte, G., Rolfo, C., Passiglia, F., Rizzo, S., Gil-Bazo, I., Fiorentino, E., Cajozzo, M., Van Meerbeeck, J. P., Lequaglie, C., Santini, D., et al. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.03.010 · Cited by 32 · cited 1×
“6 based doublets but, with higher incidence of grade 3-4 hematological toxicities [22].”
BackgroundBarata, F. J., Parente, B., Teixeira, E., Nogueira, F., Fernandes, A., Cunha, J., Araújo, A., Costa, A., & Valente, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283943.70775.a5 · Cited by 30 · cited 1×
“Five trials addressed this question [49-53] (Table 3), but only four studies were included in”
BackgroundPredictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC).
Bonanno, L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.07 · Cited by 16 · cited 1×
“receptor-associated protein 80 (RAP80) and beta-globulin, with potentially predictive role are being studied [58].”
Cited by
Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
Hsu, J. H.-M., Chang, P. M.-H., Cheng, T.-S., Kuo, Y.-L., Wu, A. T.-H., Tran, T.-H., Yang, Y.-H., Chen, J.-M., Tsai, Y.-C., Chu, Y.-S., et al. (2019) · Cancers · doi:10.3390/cancers11071003 · Cited by 68
Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V. (2020) · Science Advances · doi:10.1126/sciadv.aba5542 · Cited by 63
Metadata
- Authors
- Rossi, A., & Di Maio, M.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-04-08
- Volume
- 16
- Issue
- 6
- Pages
- 653-660
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2303758877
- Cited by
- 245
- References
- 53
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.